Michigan Cognitive Recovery Center at Lakeshore Woods is one of the only residential programs in the United States implementing the ReCODE+ Protocol, a precision medicine approach to Alzheimer’s backed by over 30 years of peer-reviewed research by Dr. Dale Bredesen.
For decades, Alzheimer’s disease has been treated as progressive and untreatable. Mainstream medicine offers drugs that may slow decline, but over 400 clinical drug trials have failed to produce a real solution.
The average lifetime cost of Alzheimer’s care exceeds $400,000 per patient. Yet no standard treatment addresses the underlying biochemical drivers of cognitive decline.
Dr. Dale Bredesen’s research at Apollo Health, built on over 30 years of laboratory science, challenges this assumption, identifying more than 36 individual contributors to cognitive decline that can each be addressed through a personalized precision medicine approach.
Metabolic imbalance including insulin resistance, inflammatory markers, nutrient deficiencies
Hormonal deficiencies including thyroid, estrogen, testosterone, cortisol dysregulation
Toxin exposure including heavy metals, mold, environmental pathogens
Structural and genetic factors including APOE4 risk, neuroinflammation, synaptic signaling imbalance
The ReCODE Protocol was developed by Dr. Dale Bredesen, an internationally recognized expert in neurodegenerative disease at Apollo Health. Rather than treating Alzheimer’s with a single drug, ReCODE identifies and addresses each individual patient’s unique biochemical contributors to cognitive decline.
Dr. Bredesen’s landmark paper demonstrating measurable cognitive improvement in patients for the first time using a multi-factor precision medicine approach. Published in a peer-reviewed medical journal.
Published in the Journal of Alzheimer’s Disease. The first clinical trial where each patient was evaluated individually and treated with a personalized precision medicine protocol.
The 2025 RCT demonstrated statistically and clinically significant improvements in cognition and depression symptoms in participants with mild to moderate Alzheimer’s disease.
Full baseline evaluation identifying each resident’s specific contributors to cognitive decline, the foundation of your personalized ReCODE report.
An individualized treatment plan generated through Apollo Health’s precision medicine platform, targeting your specific biochemical drivers of decline.
Structured learning covering the full ReCODE protocol: nutrition, sleep optimization, exercise, stress management, and metabolic health.
Sessions focused on real-world protocol application, cooking training, behavior change strategies, and personalized challenges.
Apollo Health’s KetoFLEX 12/3 brain-optimized nutrition protocol, prepared by our culinary team and tailored to each resident’s dietary needs.
Regular cognitive and lab re-testing with protocol adjustments as each resident’s health evolves throughout the 12-month program.
Full residential care within Lakeshore Woods’ Birch Building, Fort Gratiot, MI, supported by trained dementia care staff around the clock.
The average lifetime cost of Alzheimer’s care exceeds $400,000. A full 12-month MCRC program ($138,000) represents approximately one-third of that, with a protocol designed to address underlying drivers of decline, not simply manage symptoms.
Approximately 40,000 Michigan residents with Alzheimer’s may be financially qualified for this program.
✆ Call (810) 385-3185Our team will discuss candidacy, the application process, and financial options on your call.
Michigan’s first ReCODE+ residential program, now open and accepting residents. Operating in certified partnership with Apollo Health. Located within Lakeshore Woods senior living community on Lake Huron’s shoreline.
Coming soon, bringing the same certified ReCODE+ protocol to Metro Detroit and Flint-area families. The Fenton Woods location will dramatically expand access to this program within Michigan.
Call to join the waitlist: (810) 385-3185
“Treating Alzheimer’s is analogous to repairing a roof with 36 holes. The more holes you cover, the more success you have at fixing the problem.”
Dr. Dale Bredesen is an internationally recognized expert in the mechanisms of neurodegenerative diseases and a professor at UCLA. His over 30 years of laboratory research, resulting in hundreds of peer-reviewed publications, has fundamentally changed how we understand and approach cognitive decline.
In 2014, Dr. Bredesen disrupted mainstream medicine with a peer-reviewed publication demonstrating cognitive improvement in patients using a multi-step precision medicine approach, the first time such results had been documented. His continued work through Apollo Health has produced a 100-patient case study series, a 2022 clinical trial, and a 2025 Randomized Controlled Trial.
Michigan Cognitive Recovery Center operates as a certified ReCODE+ partner of Apollo Health, implementing Dr. Bredesen’s protocol in a full residential setting.
Learn more about the Bredesen Protocol at Apollo Health ➔“This program is dedicated to my brother.”
When Alzheimer’s began changing my brother, our family experienced the same fear, confusion, and uncertainty that so many families face. Every day felt like navigating the unknown, without clear answers or a path forward.
What overwhelmed us most was the lack of structure. Families are often left guessing, trying to piece together information, searching for solutions, and hoping they are making the right decisions.
The Michigan Cognitive Recovery program at Lakeshore Woods was created to bring together science, structure, and compassionate care, a program designed not only to support families, but to give them clarity, stability, and a guided path forward.
This work is deeply personal to me, and to our entire team. Every family that walks through our doors deserves hope, understanding, and the confidence that they are not facing this journey alone.
The ReCODE+ program is best suited for individuals in earlier stages of cognitive decline, where the protocol has shown the greatest measurable outcomes in published research.
Subjective Cognitive Impairment (SCI) early self-reported memory concerns without objective deficits
Mild Cognitive Impairment (MCI) measurable cognitive changes that do not yet significantly affect daily function
Early-Stage Alzheimer’s Disease diagnosed early Alzheimer’s with function intact enough to engage with the protocol
Families seeking a proactive, evidence-based approach rather than a wait-and-manage strategy
We do not claim to cure Alzheimer’s disease. We offer a comprehensive, individualized, precision medicine residential program that has shown measurable outcomes in published peer-reviewed studies at Apollo Health.
We welcome questions about the evidence and are prepared to share peer-reviewed publications with families and referring physicians.
The 2025 Randomized Controlled Trial showed statistically and clinically significant improvements in cognition and depression in participants with mild to moderate Alzheimer’s disease. Individual outcomes vary. This program is not a substitute for evaluation and ongoing care by a licensed physician.
Evidence-based guidance for families navigating Alzheimer’s and cognitive decline. Updated regularly by our clinical team.
Many families wait until Alzheimer’s symptoms worsen before seeking help. But in cognitive care, timing matters more than severity — and the window of greatest opportunity is earlier than most people realize.
Read Article ➔
Brain health is shifting from treatment to prevention. The most powerful interventions aren’t pharmaceutical — they’re lifestyle changes that anyone can begin today, and that form the foundation of the ReCODE+ protocol.
Read Article ➔
Medications address symptoms, not root causes. Understanding the limitations of pharmaceutical-only approaches — and what precision medicine adds — is essential for every family navigating a diagnosis.
Read Article ➔
Families facing an Alzheimer’s diagnosis must choose between traditional symptom management and a precision medicine approach that targets root causes. Here is a clear, honest comparison to help you decide.
Read Article ➔The Vineyards in Fresno, California, the only other active ReCODE+ residential program in the United States, is at capacity. Michigan Cognitive Recovery Center at Lakeshore Woods has availability today. Don’t wait.
✆ (810) 385-3185